Displaying results 1 - 25 of 125 for breast cancer. Subscribe to this search
(BPT) - When Ginny Knackmuhs beat early-stage breast cancer and had routine checkups during the years that followed, she thought the disease was behind her. But in 2009, she was shocked to receive another diagnosis of breast cancer. This time it was metastatic, the most advanced kind.
Living with breast cancer when there's no cure
Women with a family history of BRCA2 mutations who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population, according to a recent study.
New breast cancer study results published in The Lancet compare targeted radiotherapy during surgery with ZEISS INTRABEAM to traditional post-surgical radiotherapy treatment
JENA, Germany--(BUSINESS WIRE)--Dec 2, 2013--Results of the TARGIT-A clinical trial published in The Lancet
STAMFORD, Conn.--(BUSINESS WIRE)--Dec 2, 2013--(Booth #2539 South Building)-FUJIFILM Medical Systems U.S.A., Inc. announced today 510(k)clearance from the U.S Food and Drug Administration (FDA) of its Gadolinium and Cesium digital X-ray detectors for pediatric use. Sizes that are available include: 24x30cm, 14x17 and 17x17. The smallest format 24x30cm cesium iodide detector is specifically designed to offer high DQE performance for low dose x-ray exams such as for small patients and anatomy such as extremities, shoulders, c-spines and more.
STAMFORD, Conn.--(BUSINESS WIRE)--Dec 1, 2013--Booth #2539 South Building -- FUJIFILM Medical Systems U.S.A., Inc. will highlight its new floor-mounted digital x-ray system, the latest addition to its growing portfolio of advanced digital radiography solutions at the 99 th annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL. The new FDR D-EVO Suite FS is a space saving DR room solution, built for reliability and performance to handle the busiest radiology departments.
STAMFORD, Conn.--(BUSINESS WIRE)--Dec 1, 2013--(Booth #2539 South Building) – FUJIFILM Medical Systems U.S.A., Inc. is showcasing its comprehensive Synapse portfolio at the 99th annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL. The Synapse family of products combined provides management of the complete patient record, insure diagnostic integrity while providing fast, secure access to clinical users via web platforms or mobile devices.
CHICAGO--(BUSINESS WIRE)--Dec 1, 2013--GE Healthcare, a unit of General Electric Company (NYSE:GE), introduced today the new Invenia Automated Breast Ultrasound System (ABUS) at the 2013 Radiological Society of North America (#RSNA13) annual meeting. ABUS is used to answer the need of detecting additional cancer in women where mammography alone may be insufficient due to their greater breast density. Featuring new automated compression tools for enhanced workflow and ergonomics†, the automated breast ultrasound system provides physicians a new way to look at dense breast tissue that can allow them to improve breast cancer detection by up to 35.7 percent over mammography alone.
It's almost time to say goodbye to Lauren Dorsett before she moves to California, but we couldn't let her leave without letting a few people say goodbye.
(BPT) - An ever-growing popular concept in personal healthcare is the idea of the empowered patient (also known as being an advocate for your health). This term can mean different things to different people, but the general concept is that an individual makes well-informed health decisions based on research and conversations with their physician. One person who has applied this concept to her own personal health is Florida-native, Leslie Cunningham.
NEW YORK (AP) — Amy Robach (ROH'-bahk) of ABC News says she can't wait to get back to work following her double mastectomy but has more cancer treatments ahead of her.
CHICAGO (AP) — Identical twins who both had breast cancer are recovering after rare reconstruction surgery at the University of Chicago Medical Center.
Breast cancers that initially respond to hormone therapies, like tamoxifen, eventually become resistant to treatment. A new study finds this may be because of a mutation in the receptor present in the cancer cell to which tamoxifen binds.
JOHANNESBURG (AP) — Nelson Mandela's family is no stranger to the public eye —its successes and trials have been aired for decades through books, films and the news media.
Your daily look at late-breaking news, upcoming events and the stories that will be talked about today:
(NewsUSA) - Michele Vela, 60, of Los Angeles was always diligent about her annual mammograms. Despite this, Michele was diagnosed with advanced (stage IV) breast cancer several years ago. After her diagnosis, Michele retired from her 33-year career as a postal worker and committed herself to fighting the disease. The experience gave her a new perspective, and she sought to make the most of every day: connecting with friends, playing golf and making time to take care of herself. "I was so frightened when I was first diagnosed with advanced breast cancer, but it is important to have hope," Vela said. Breast cancer is considered advanced when the cancer has spread to other parts of the body, for example, to tissue near the breast (known as "locally advanced") or to remote areas of the body, such as the brain, bones or liver (known as "metastatic"). Unlike some early-stage breast cancers, advanced breast cancer is not curable. Women with advanced breast cancer remain on treatment for the rest of their lives. In Michele's case, the cancer had spread to her bones. After testing, Michele learned that she had advanced hormone receptor-positive (HR+)/HER2 negative breast cancer. Advanced HR+/HER2 negative breast cancer is the most common form of the disease and is fueled by hormones such as estrogen and progesterone. With treatment, most recently including the common hormone therapy letrozole, Michele's cancer was kept under control for several years. Recently, Michele received the news she feared: the cancer had spread again, this time to her ribs. Michele worked closely with her doctor to learn about her options. Postmenopausal women with advanced HR+/HER2 negative breast cancer are often treated with hormone therapy, but resistance to hormone therapy can develop, causing tumors to grow and spread. After progressing on a treatment regimen including letrozole, Michele started a new treatment plan, which included Afinitor (everolimus tablets) and exemestane. Afinitor targets a specific pathway that may help extend the benefit of hormone therapy. The FDA approved Afinitor in 2012 for postmenopausal women with advanced HR+/HER2 negative breast cancer in combination with exemestane (a commonly used option) after failure of treatment with letrozole or anastrozole, offering another option for patients. "My diagnosis helped me realize how precious my life is and the people around me are," Vela said. "But the most important thing I've learned throughout my journey with the disease is that we are the beneficiaries of 21st-century medicine, and there are a lot of treatment options out there." A clinical trial found that adding Afinitor to the drug exemestane more than doubled the time women lived without tumor growth, to a median of 7.8 months compared to treatment with exemestane alone at a median of 3.2 months. In this study, the most common adverse reactions (incidence ? 30 percent) associated with Afinitor were mouth sores, infections, rash, tiredness, diarrhea and decreased appetite. Afinitor can cause serious side effects, including lung or breathing problems, infections and kidney failure, which can sometimes be fatal. If patients experience these side effects, they may need to stop taking Afinitor for a while or use a lower dose. Currently available data have not shown an increase in overall survival. Additional data will be available in the future. Afinitor® (everolimus) Important Safety Information Patients should not take Afinitor if they are allergic to Afinitor or to any of its ingredients. Before taking Afinitor, patients should tell their healthcare provider if they are allergic to sirolimus (Rapamune®) or temsirolimus (Torisel®). Afinitor can cause serious side effects, including lung or breathing problems, infections, and kidney failure, which can even be fatal. If patients experience these side effects, they may need to stop taking Afinitor for a while or use a lower dose. Patients should follow their healthcare provider's instructions. In some patients, lung or breathing problems may be severe and can even be fatal. Patients should tell their healthcare provider right away if they have any of these symptoms: new or worsening cough, shortness of breath, chest pain, difficulty breathing or wheezing. Afinitor may make patients more likely to develop an infection, such as pneumonia, or a bacterial, fungal or viral infection. Viral infections may include reactivation of hepatitis B in people who have had hepatitis B in the past. In some people, these infections may be severe and can even be fatal. Patients may need to be treated as soon as possible. Patients should tell their healthcare provider right away if they have a temperature of 100.5?F or above or chills, or do not feel well. Symptoms of hepatitis B or infection may include the following: fever, chills, skin rash, joint pain and inflammation, tiredness, loss of appetite, nausea, pale stools or dark urine, yellowing of the skin or pain in the upper right side of the stomach. Afinitor may cause kidney failure. In some people, this may be severe and can even be fatal. Patients should have tests to check their kidney function before and during their treatment with Afinitor. Common side effects include mouth ulcers. Afinitor can cause mouth ulcers and sores. Other common side effects include infections; feeling weak or tired; nausea and vomiting; skin problems; headache; weight loss; loss of appetite; cough; diarrhea; fever; swelling of the hands, arms, legs, feet, face or other parts of the body; joint pain, abnormal taste; stomach-area (abdomen) pain, nose bleeds, seizures, increased blood cholesterol and sugar levels, decreased blood phosphate levels, low red and white blood cells and the absence of menstrual periods (menstruation). Please see full Prescribing Information for Afinitor available at Afinitor.com. Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc. For more information, talk to your doctor and visit www.Afinitor.com. AFB-1073449 10/2013
NEW YORK (AP) — ABC News correspondent Amy Robach says she has breast cancer, a month after she was given a mammogram on the air for a "Good Morning America" story.
A new study shows young girls with higher body mass index, above the 85th percentile, tend to be starting puberty earlier. But, what does this mean for the health of your child?
Breast augmentation is one of the most common cosmetic surgeries performed in the United States, But there are other considerations for women wanting reconstruction following a mastectomy to treat or prevent breast cancer.
CAMPBELL, Cali. (Ivanhoe Newswire) – Thirty-three percent of women choose to get breast reconstruction surgery after having a mastectomy. This low rate may come as a surprise to some, but when you consider today’s long process of using needle-based, saline expanders, you might see why some women opt out of this process. Now, a new remote controlled device is helping ease some of that pain and fear.